- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Direct immunofluorescence.
Displaying page 1 of 1.
EudraCT Number: 2020-000287-32 | Sponsor Protocol Number: D325AC00002 | Start Date*: 2020-12-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD) | |||||||||||||
Medical condition: Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002391-14 | Sponsor Protocol Number: SAWV1003 | Start Date*: 2005-09-29 |
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | ||
Full Title: Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study | ||
Medical condition: ocular mucous membrane pemphigoid | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005987-67 | Sponsor Protocol Number: AK802 | Start Date*: 2021-12-22 | |||||||||||
Sponsor Name:Akari Therapeutics Plc | |||||||||||||
Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem... | |||||||||||||
Medical condition: moderate to severe bullous pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000756-42 | Sponsor Protocol Number: MEX0111 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dompé s.p.a. | |||||||||||||
Full Title: A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. | |||||||||||||
Medical condition: active bullous pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002333-40 | Sponsor Protocol Number: ARGX-113-1701 | Start Date*: 2018-01-31 | ||||||||||||||||
Sponsor Name:argenx BVBA | ||||||||||||||||||
Full Title: An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vul... | ||||||||||||||||||
Medical condition: Pemphigus (Vulgaris or Foliaceus) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002836-18 | Sponsor Protocol Number: AK801 | Start Date*: 2018-05-07 | |||||||||||
Sponsor Name:Akari Therapeutics Plc. | |||||||||||||
Full Title: A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects | |||||||||||||
Medical condition: Mild to Moderate Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004361-32 | Sponsor Protocol Number: KKS-166 | Start Date*: 2013-02-26 |
Sponsor Name:Philipps-Universität Marburg | ||
Full Title: Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study | ||
Medical condition: Bullous pemphigoid (BP) is the most frequent blistering autoimmune disease of the skin. The disease itself is characterized by the development of bullous lesions, frequently following a prodromal p... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-001245-41 | Sponsor Protocol Number: 2005/Diaminodiphenylsulfon/1 | Start Date*: 2005-09-23 |
Sponsor Name:Department of Dermatology, Hospital of the Medical University Graz | ||
Full Title: A single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dapsone in adult patients with cutaneous leukocytoclastic vasculitis | ||
Medical condition: Cutaneous leukocytoclastic vasculitis is an inflammatory vascular disease and is manifested clinically by a spectrum of cutaneous lesions, although “papable purpura” is its clinical hallmark. The p... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2014-000382-41 | Sponsor Protocol Number: WA29330 | Start Date*: 2015-03-06 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris | |||||||||||||
Medical condition: Pemphigus Vulgaris (PV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000211-24 | Sponsor Protocol Number: IMAT-PV | Start Date*: 2013-10-01 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuva... | |||||||||||||
Medical condition: patients with Pemphigus vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004040-70 | Sponsor Protocol Number: BUC-56/PBC | Start Date*: 2008-05-15 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsu... | |||||||||||||
Medical condition: PBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflamm... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) NL (Completed) FI (Completed) ES (Completed) HU (Completed) GB (Completed) LT (Completed) DK (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002443-42 | Sponsor Protocol Number: GS-US-427-4024 | Start Date*: 2017-01-09 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003528-62 | Sponsor Protocol Number: EDP305-201 | Start Date*: 2018-12-05 | |||||||||||
Sponsor Name:Enanta Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis... | |||||||||||||
Medical condition: Primary Biliary Cholangitis (PBC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) AT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001370-20 | Sponsor Protocol Number: OPV116910 | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:Glaxo Group Ltd | |||||||||||||
Full Title: OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris | |||||||||||||
Medical condition: Pemphigus Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) HR (Completed) GR (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002915-23 | Sponsor Protocol Number: ARGX-113-1904 | Start Date*: 2021-01-25 | ||||||||||||||||
Sponsor Name:argenx BV | ||||||||||||||||||
Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS) | ||||||||||||||||||
Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004174-64 | Sponsor Protocol Number: DMX-200-301 | Start Date*: 2022-03-08 | ||||||||||||||||
Sponsor Name:Dimerix Bioscience Pty Ltd | ||||||||||||||||||
Full Title: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving... | ||||||||||||||||||
Medical condition: Focal segmental glomerulosclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003564-37 | Sponsor Protocol Number: PRN1008-005 | Start Date*: 2016-04-21 | |||||||||||
Sponsor Name:Principia Biopharma Australia Pty Ltd | |||||||||||||
Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn... | |||||||||||||
Medical condition: Pemphigus: Pemphigus Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000060-22 | Sponsor Protocol Number: 2020/0424/HP | Start Date*: 2023-04-03 | |||||||||||||||||||||
Sponsor Name:CHU de Rouen | |||||||||||||||||||||||
Full Title: Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corti... | |||||||||||||||||||||||
Medical condition: Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (PF). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004666-26 | Sponsor Protocol Number: 2015/208/HP | Start Date*: 2017-07-19 | |||||||||||||||||||||
Sponsor Name:CHU-Hôpitaux de Rouen | |||||||||||||||||||||||
Full Title: Randomised double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid | |||||||||||||||||||||||
Medical condition: severe forms of mucous membrane pemphigoid | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000713-32 | Sponsor Protocol Number: CAEL101-302 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:Caelum Biosciences, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dysc... | |||||||||||||
Medical condition: stage IIIa cardiac AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) PL (Trial now transitioned) BE (Completed) IT (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) NL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
